WO2009117936A1 - Composition pharmaceutique à effets antipyrétiques, anti-inflammatoires et analgésiques et son procédé de préparation - Google Patents

Composition pharmaceutique à effets antipyrétiques, anti-inflammatoires et analgésiques et son procédé de préparation Download PDF

Info

Publication number
WO2009117936A1
WO2009117936A1 PCT/CN2009/070955 CN2009070955W WO2009117936A1 WO 2009117936 A1 WO2009117936 A1 WO 2009117936A1 CN 2009070955 W CN2009070955 W CN 2009070955W WO 2009117936 A1 WO2009117936 A1 WO 2009117936A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
component
achyranthes
chuanxiong
pharmaceutical composition
Prior art date
Application number
PCT/CN2009/070955
Other languages
English (en)
Chinese (zh)
Inventor
赵学军
张昊
龙彦纲
郭芳芳
Original Assignee
深圳力瑞医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳力瑞医药科技有限公司 filed Critical 深圳力瑞医药科技有限公司
Publication of WO2009117936A1 publication Critical patent/WO2009117936A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the invention relates to a pharmaceutical composition having antipyretic, anti-inflammatory and analgesic effects and a preparation method thereof, and belongs to the field of traditional Chinese medicine. Background technique
  • Another object of the present invention is to provide a process for the preparation of a pharmaceutical composition having antipyretic, anti-inflammatory and analgesic effects.
  • the raw material of the pharmaceutical composition of the present invention is: 10-50 parts of raw gypsum as a medicinal drug; 5-15 parts of Chuanxiong as a drug and 5-25 parts of a white peony.
  • it is 25 parts of gypsum, 10 parts of Chuanxiong and/or 15 parts of white peony.
  • the invention also provides a preparation method of the active ingredient of the pharmaceutical composition, wherein:
  • the preparation method includes:
  • the preparation method comprises:
  • the components 1 and 2 are combined, pulverized into powder, and uniformly mixed to prepare an active ingredient of the medicament of the present invention.
  • the raw material medicine of the pharmaceutical composition of the present invention may also be: 10-50 parts of raw gypsum as a drug, 5-15 parts of Chuanxiong as a drug, and 5-25 parts of white peony; 5-20 parts of cohosh as an adjuvant 5-25 parts of Sichuan Achyranthes or Achyranthes.
  • the invention also provides a preparation method of the active ingredient of the pharmaceutical composition, wherein:
  • the preparation method includes:
  • the preparation method includes:
  • the components 1 and 2 are combined, pulverized into powder, and uniformly mixed to prepare an active ingredient of the medicament of the present invention.
  • the raw material medicine of the pharmaceutical composition of the present invention may also be: 10-50 parts of raw gypsum as a drug, 5-15 parts of Chuanxiong as a drug, and 5-25 parts of white peony; 5-20 parts of cohosh as an adjuvant 5-25 parts of Sichuan Achyranthes or Achyranthes, 1_10 parts of Coptis or 5-30 parts of Rehmanniae.
  • it is 25 parts of raw gypsum, 10 parts of Chuanxiong and/or 15 parts of white peony, 10 parts of Cimicifuga, 15 parts of Achyranthes bidentata or Achyranthes, 3 parts of Rhizoma Coptidis or 15 parts of Rehmannia glutinosa.
  • the invention also provides a preparation method of the active ingredient of the pharmaceutical composition, wherein:
  • the preparation method includes:
  • the preparation method includes:
  • the components 1 and 2 are combined, pulverized into powder, and uniformly mixed to prepare an active ingredient of the medicament of the present invention.
  • the raw material medicine of the pharmaceutical composition of the present invention may also be: 10-50 parts of raw gypsum as a monarch; 5-15 parts of Chuanxiong as a foreign medicine and 5-25 parts of white peony; 3-10 parts of asarum as an adjuvant Or live 5-15 copies.
  • it is 25 parts of gypsum, 10 parts of Chuanxiong and/or 15 parts of white peony, 6 parts of asarum or 10 parts of medlar.
  • the invention also provides a preparation method of the active ingredient of the pharmaceutical composition, wherein:
  • the preparation method includes:
  • the components 2 and 3 are combined, pulverized, and sprayed with the component 1, and mixed to prepare an active ingredient of the medicament of the present invention.
  • the raw material medicine of the pharmaceutical composition of the present invention may also be: 10-50 parts of raw gypsum as a monarch; 5-15 parts of Chuanxiong as a foreign medicine and 5-25 parts of white peony; 3-10 parts of asarum as an adjuvant Or live 5-15 parts, berberine 1_10 parts or rehmannia 5_30 parts.
  • it is 25 parts of gypsum, 10 parts of Chuanxiong and/or 15 parts of white peony, 6 parts of asarum or 10 parts of medlar, 3 parts of berberine or 15 parts of rehmannia.
  • the invention also provides a preparation method of the active ingredient of the pharmaceutical composition, wherein:
  • the preparation method includes:
  • the preparation method comprises:
  • the components 2 and 3 are combined, pulverized, and sprayed with the component 1, and mixed to prepare an active ingredient of the medicament of the present invention.
  • the raw material medicine of the pharmaceutical composition of the present invention may also be: 10-50 parts of raw gypsum as a drug, 5-15 parts of Chuanxiong as a drug, and 5-25 parts of white peony; 5-20 parts of cohosh as an adjuvant 5-25 parts of Sichuan Achyranthes or Achyranthes, 3_10 parts of Asarum or 5-15 parts of Astragalus.
  • it is 25 parts of raw gypsum, 10 parts of Chuanxiong and/or 15 parts of white peony, 10 parts of Cimicifuga, 15 parts of Achyranthes bidentata or Achyranthes, 6 parts of Asarum or 10 parts of medlar.
  • the invention also provides a preparation method of the active ingredient of the pharmaceutical composition, wherein:
  • Chuanxiong and Radix Paeoniae Alba are medicinal herbs, Cimicifuga, Achyranthes bidentata or Achyranthes, Astragalus or Poria
  • the preparation method includes:
  • the preparation method includes:
  • the components 2 and 3 are combined, pulverized, and sprayed with the component 1, and mixed to prepare an active ingredient of the medicament of the present invention.
  • the raw material medicine of the pharmaceutical composition of the present invention may also be: 10-50 parts of raw gypsum as a drug, 5-15 parts of Chuanxiong as a drug, and 5-25 parts of white peony; 5-20 parts of cohosh as an adjuvant 5-25 parts of Achyranthes bidentata or Achyranthes, 3_10 parts of Asarum or 5-15 parts of medlar, 1-10 parts of Rhizoma Coptidis or 5-30 parts of Rehmannia glutinosa.
  • it is 25 parts of raw gypsum, 10 parts of Chuanxiong and/or 15 parts of white peony, 10 parts of cohosh, 15 parts of Achyranthes bidentata or Achyranthes, 6 parts of Asarum or 10 parts of medlar, 3 parts of Coptis or 15 parts of Rehmannia.
  • the invention also provides a preparation method of the active ingredient of the pharmaceutical composition, wherein:
  • the preparation methods include:
  • the preparation method includes:
  • the present invention provides the use of the above various pharmaceutical compositions for the preparation of a medicament having antipyretic, anti-inflammatory and analgesic effects.
  • the medicinal materials used in the present invention are:
  • the Chuanxiong of the present invention is an umbelliferous plant Dry rhizome of c/raa «xo «g Hort.
  • the white pheasant of the present invention is the genus Angeiica dahurica (Fisch.ex Hoffm.) Benth. Et Hook.f. or Angelica dahurica (Fisch.ex Hoffm.) Benth. Et Hook. f. var. Formosana (Boiss.) The dry root of Shan etYuan.
  • the gypsum of the present invention is a sulfate-based mineral anhydrite gypsum, mainly containing aqueous calcium sulfate (CaS(V2H 2 0).
  • the cohosh is the Ranunculaceae plant Cimicifuga heracleifolia Kom., Xing Ansheng Hempicifuga dahurica (Turcz.) Maxim or Cimicifuga foetida L.
  • the achyranthes of the present invention is a dried root of the achyranthes cv, c/z ra «t1 ⁇ 2s bidentata lume, and its processed products, including achyranthes and achyranthes.
  • the Achyranthes bidentata of the present invention is a dried root of Cyathula officinalis Kuan and its processed products, including Chuan Niu Knee and Jiuchuan Achyranthes.
  • the coptis of the present invention is a dried rhizome of Coptis chinensis Franch., Coptis deltoidea C.Y.Cheng et Hsiao or Coptis teeta Wall., including Weilian, Yalian and Yunlian.
  • the rehmannia of the present invention is a root of Rehmannia glutinosa Libosch., which includes fresh rehmannia and rehmannia.
  • the asarum of the present invention is Aristolochia, Asar, heteroaroids Fr. Schmidt var. mandshuricum (Maxim.) Kitag. Asarum sieboldii Miq. var. seoulense Nakai or Huaxinxin
  • the scorpion of the present invention is a dried root and root of the genus Umbelliferae Notopter g M incisum Ting ex HTChang or Notoptery gium forbesii Boiss.
  • the pharmaceutical composition of the present invention can be prepared into any conventional internal preparation by a conventional method of a traditional Chinese medicine preparation.
  • these raw materials can be ground into powder and uniformly mixed into powders; these raw materials can be decoctioned or ethanol extracted together, or these raw materials can be extracted by modern techniques, such as by supercritical carbon dioxide (SFE-C0 2 ). Extraction or ultrasonic extraction, etc., then concentrated and dried.
  • the active ingredient of the pharmaceutical composition of the present invention can be prepared into any conventional internal dosage form by adding various conventional excipients required for preparing different dosage forms, such as disintegration, lubricant, adhesive, etc., into a conventional internal dosage form, such as Granules, granules, tablets, pills, pills, capsules, soft capsules, oral liquids, mixtures, and the like.
  • the pharmaceutical composition of the present invention has antipyretic, anti-inflammatory and analgesic effects, and is particularly suitable for treating fever and head pain caused by a cold, oral ulcer or periodontitis, various headaches and the like.
  • TCM theory since the drug of the present invention is mainly used to clear the heat of the yang or the spleen and stomach, it is of course suitable for the Chinese medicine to say that Yangming gas heat, Yangming stagnation, spleen and stomach fire, headache and the like Treatment of the card.
  • the idea of the present invention is derived from the analysis of traditional Chinese medicine clinical pathogenesis of various colds, oral ulcers and periodontitis.
  • the pharmaceutical composition of the present invention reuses the raw gypsum of Xingan cold and cool, and the heat of Zhiqing gas is divided; the use of Chuanxiong, Baiji is the minister, and the evil of the six sexes; the use of Cimicifuga, Sichuan Achyranthes or Achyranthes, Asarum ⁇ ⁇ ⁇ , , , , , ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ; ; ; Therefore, the pharmaceutical composition of the invention can not only rapidly detoxify, but also effectively alleviate the head and body pain caused by the six genital diseases.
  • the pharmaceutical composition of the invention reuses the raw gypsum of Xingan cold and cool, and the heat of the spleen and stomach of Zhiqingzhong; the Chuanxiong and/or the white peony which has the functions of hurricane, blood circulation and analgesic function, the spleen and stomach, the evil of blood, constitutes
  • the basic formula of the pharmaceutical composition of the present invention wherein Chuanxiong or Baiji can be used alone, and Chuanxiong and Baiji can also be used together to enhance the therapeutic effect. All three groups are obtained based on the same Chinese medicine prescription.
  • the present inventors have unexpectedly found in clinical practice that such a combination can obtain a better effect than a single drug substance alone, and a new synergistic effect is produced, which is subsequently confirmed by a series of animal experiments, thereby completing the present invention.
  • the core part of the pharmaceutical composition is a part of the pharmaceutical composition.
  • the inventors combined with the central idea of "drugs with syndromes" in traditional Chinese medicine, aiming at different patient constitutions or different complications, accompanied by Cimicifuga, Achyranthes or Achyranthes, Astragalus, Astragalus, etc. Fire; berberine, rehmannia can not both clear heat and cool blood, have nourishing yin and nourishing liquid. Therefore, based on the basic formula, the scope of application after various adjuvant medicines is more extensive; through repeated clinical verification, the inventors confirmed that the pharmaceutical composition has good curative effect on the burning, swelling and pain of the above patients. .
  • the drugs prepared by the above-mentioned raw materials have unique antipyretic, anti-inflammatory and analgesic effects, and therefore can be widely applied to the treatment of various fever, inflammation and pain diseases, and are particularly suitable for colds. Caused by fever or head pain, oral ulcers and periodontitis, various headaches and other symptoms. Since the combination of the drug substance of the pharmaceutical composition of the present invention obviously reflects the effect of the Chinese medicine said to clear the symptoms of Yangming gas heat, Yangming stagnation, spleen and stomach fire, headache, etc., the above-mentioned TCM syndrome is of course belonging to the drug combination of the present invention. The scope of treatment of the object. Moreover, the pharmaceutical combinations of the present invention are not disclosed in the prior art and belong to a completely new combination of drugs.
  • the types and contents of the active ingredients and toxic components of the raw materials extracted by different extraction methods may be different. Therefore, if different extraction processes are selected for the same drug combination, the dosage ratio of the raw materials should also be adjusted accordingly.
  • the raw material medicine of the pharmaceutical composition of the present invention may be used in an amount of 10-15 parts by weight, and the alcohol extraction, supercritical extraction or ultrasonic extraction may only require 3-6 parts by weight, and the white peony water extraction may be 5-25 parts by weight. Alcohol extraction, supercritical extraction or ultrasonic extraction may only require 2-8 parts by weight, but the amount of other raw materials with which it is compatible may be maintained at a relatively stable level.
  • mice SPF grade, weight 18 ⁇ 22g, ? 3 Both use (female mice by hot plate method, male mice for ear swelling); SD rats, SPF grade, weight 180 ⁇ 220g, ? 3 is also used. New Zealand white rabbits weigh 2 to 3 kg. 1.2 Instrument
  • GJ-8420 hot plate instrument (Ninghai Baishi Electronic Medical Instrument Factory); electronic balance (Sartorius, BP121S); visible / ultraviolet spectrophotometer (UV2450, Japan SHIMADZU).
  • the pharmaceutical composition of the present invention N1-N49 (see the notes for the types of the drug substance of each pharmaceutical composition, see the dosage of each drug substance.
  • each of the drug substances given in the invention is administered by intragastric administration, and is mixed with distilled water to form a desired concentration; aspirin enteric-coated tablets (Shaanxi Bailu Pharmaceutical Co., Ltd., commercially available); Evansland (Uni-CHEM, lot : commercially available); dry yeast (Hubei Angel Yeast Co., Ltd., commercially available, with steamed water before use, formulated with 20% suspension for experimental use); Pertussis vaccine, diphtheria, tetanus toxoid mixed preparation, Lanzhou Institute of Biological Products, Ministry of Health; glacial acetic acid, xylene are domestic analytical pure.
  • the selected rabbits were randomly divided into blank control group, positive drug aspirin group, raw gypsum group, Chuanxiong group, white peony group and N1 and N49 groups of the present invention (54 groups in total, 8 rats in each group), respectively.
  • Rats were acclimated for 3 days in the laboratory (22 ⁇ 1 degree at room temperature), and the anal temperature was measured twice daily for 2 consecutive days. Rats with a basal body temperature of 37 37.7 degrees were injected with a 20% yeast suspension on the back skin ( 10mg/kg).
  • the body temperature was increased by 1 degree or more, and randomly divided into 54 groups, 10 in each group, which were blank control group, positive drug aspirin group, raw gypsum group, Chuanxiong group, white peony group and the present invention N1 to In the N49 group, the corresponding water or drug is administered by gavage, and the dose of the drug of the present invention is 6.0 g of crude drug/Kg body weight (which is a clinical equivalent dose).
  • the body temperature was measured at 1.5 h 2 h 3 h after administration, and the body temperature change value (the difference between the body temperature and the basal body temperature measured after the drug) was calculated and compared.
  • Group U agent M (g/kg) basal body temperature
  • Blank control group 37.45 ⁇ 0.16 0.85 ⁇ 0.21 1.48 ⁇ 0.25 1.1 ⁇ 0.24
  • Raw gypsum group 6.0 37.67 + 0.56 0.77 + 0.17 1.08 + 0.20 1.25 + 0.11
  • Chuanxiong group 6. 0 37. 65 + 0. 12 0. 80 + 0. 18 0. 92 + 0. 19 1. 06 + 0. 32 6.
  • Aspirin group 0. 05 37. 44 + 0. 16 1. 11 ⁇ 0. 16* 1. 43 + 0. 36** 0. 82 + 0. 22**
  • ⁇ The effect is better than ⁇ 4—N15;
  • mice Female mice were taken and screened with a hot plate pain tester (temperature 55 ⁇ 0.5 degrees) before the formal experiment. The time required to insert the pain tester to the hind paw was recorded (S), and the 5 ⁇ 30S reaction was selected. Stable, non-jumping mice were used for experimental purposes as a pre-dose pain threshold. 540 mice were randomly selected and randomly divided into 54 groups, 10 in each group, which were blank control group, positive drug aspirin group, raw gypsum group, Chuanxiong group, white peony group and N1 to N49 groups of the present invention. The stomach is administered with the corresponding water or drug, and the dose of the medicament of the present invention is 7.5 g of crude drug/kg of body weight (which is a clinically equivalent dose).
  • N36 7. 5 13. 2 ⁇ 2. 5 17. 5 ⁇ 3. 7 30. 7 ⁇ 2. 6** ⁇ 35. 63 + 6.53**
  • the curative effect is better than ⁇ 1— ⁇ 3;
  • ⁇ The effect is better than ⁇ 4—N15;
  • mice Take 648 mice, ? 3 halves were randomly divided into 54 groups, 12 in each group, which were blank control group, positive aspirin group, raw gypsum group, Chuanxiong group, white peony group and N1 to ⁇ 49 groups of the present invention, respectively, orally administered with corresponding water or
  • the drug, the dose of the medicament of the present invention is 7.5 g of crude drug/Kg body weight (for clinical equivalent dose), administered by intragastric administration for 4 days, once a day, and 1 hour after the last administration, each group of mice is intraperitoneally injected with 1% acetic acid 10 ml. /kg, record and compare the number of writhings that appear in mice within 15 minutes after injection of acetic acid.
  • mice were randomly divided into 54 groups (10 in each group), which were blank control group, positive drug aspirin group, raw gypsum group, Chuanxiong group, white peony group and N1 to N49 groups of the present invention, respectively.
  • the dosage of the medicament of the present invention is 7.5 g of crude drug / Kg body weight (for clinical equivalent dose), intragastric administration for 4 days, once a day, 1 hour after the last administration, and the right ear of each group of mice Evenly spread xylene (40 ml/head) and use the left ear as a control. After lh, the mice were sacrificed by cervical vertebrae. Two ears were cut along the baseline of the auricle.
  • Group N dose (g/kg) Swelling degree (mg)
  • the curative effect is better than ⁇ 1— ⁇ 3;
  • ⁇ The effect is better than ⁇ 4—N15;
  • mice Take 540 mice, ? 3 halves were randomly divided into 54 groups (10 in each group), which were blank control group, positive drug aspirin group, raw gypsum group, Chuanxiong group, white peony group and N1 to ⁇ 49 group of the present invention, respectively.
  • Water or drug the dose of the drug of the present invention is 7.5 g of crude drug / Kg body weight (for clinical equivalent dose), administered intragastrically for 4 days, once a day, and intravenously injected with 0 at the end of 1 hour after the last administration.
  • N1-N49 of the present invention has a significant antipyretic effect on the fever of rabbits induced by yeast and white bacillus, and significantly increases the pain threshold of the hot plate method of mice, and inhibits the acetic acid.
  • the mouse writhing reaction significantly inhibits the increase in capillary permeability induced by acetic acid and the swelling of the mouse's ear caused by xylene; and in terms of overall efficacy, N4-N15 acts better than N1-N3, N16-
  • the effect of N39 is better than that of N4-N15, and the effect of N40-N49 is better than that of N16_N39.
  • N1-N3 has obvious antipyretic, analgesic and anti-inflammatory effects, and can be used for the treatment of related diseases including cold fever, head and body pain, mouth ulcers, periodontitis, and various headaches.
  • N41 raw gypsum 1 ⁇ , ⁇ , ⁇ , ⁇ , ⁇
  • the chuanxiong and/or white peony were extracted with 8 times 70% ethanol for 3 times, each time for 1 hour, filtered, and the filtrate was combined.
  • the ethanol was recovered under reduced pressure and concentrated to a relative density of 1.05 to 1.15 (70 to 85 ° C heat).
  • the mixture was allowed to stand, filtered, and the filtrate was concentrated under reduced pressure at 60 ° C to a thick paste, and dried to give component 1.
  • the raw gypsum was decocted with 10 times of water for 3 times, each time for 1 hour, filtered, and all the filtrates were combined and concentrated to relative density. 1.05 to 1.15 (heat test at 70 to 85 °C), allowed to stand, filtered, and the filtrate was concentrated and dried to give component 2.
  • Combine component 1 and component 2 add appropriate amount of powdered sugar, mix well, extrude and granulate, dry at 60 ° C or below, whole, and dispense, then obtain; or dry the thick paste to dry paste under reduced pressure, pulverize into Dry paste powder, dry granulation, that is.
  • the raw gypsum and the cohosh are added with 10 times of water for 3 times, each time for 1 hour, filtered, and all the filtrates are combined and concentrated to a relative density of 1.05 ⁇ 1.15 (heat test at 70 ⁇ 85 °C), allowed to stand, filtered, and concentrated. , dry, get component 2.
  • the raw gypsum and the cohosh are boiled 10 times with water for 3 times, each time for 1 hour, filtered, the filtrates are combined, and concentrated to relative density.
  • the Chuanxiong, Baiji, and Sichuan Achyranthes were extracted with 8 times 60% ethanol for 3 times, each time for 1 hour, filtered, and the filtrate was combined, and the ethanol was recovered under reduced pressure, and dried under reduced pressure at 60 ° C to obtain component 3.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une composition pharmaceutique à effets antipyrétiques, anti-inflammatoires et analgésiques, son procédé de préparation et son utilisation. Ladite composition pharmaceutique comprend 10-60 parts en gypse, et au moins un matériau choisi dans le groupe constitué de chuanxiong 5-15 parts et/ou angélica 5-25 parts en poids. S'il y a lieu, on peut ajouter dans la composition plusieurs matières médicinales chinoises additionnelles, ladite composition pouvant alors être préparée dans n'importe quelle forme pharmaceutique orale couramment utilisée.
PCT/CN2009/070955 2008-03-25 2009-03-24 Composition pharmaceutique à effets antipyrétiques, anti-inflammatoires et analgésiques et son procédé de préparation WO2009117936A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200810065869.9 2008-03-25
CN2008100658699A CN101254227B (zh) 2008-03-25 2008-03-25 一种具有解热、抗炎和镇痛作用的药物组合物及其制备方法

Publications (1)

Publication Number Publication Date
WO2009117936A1 true WO2009117936A1 (fr) 2009-10-01

Family

ID=39889550

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2009/070955 WO2009117936A1 (fr) 2008-03-25 2009-03-24 Composition pharmaceutique à effets antipyrétiques, anti-inflammatoires et analgésiques et son procédé de préparation

Country Status (2)

Country Link
CN (1) CN101254227B (fr)
WO (1) WO2009117936A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103585289A (zh) * 2012-08-15 2014-02-19 四川济生堂药业有限公司 一种预防或治疗肠易激综合症的药物组合物
CN112618648A (zh) * 2020-12-25 2021-04-09 李玲 一种快速退热的中药组合物及其制备方法
CN116870076A (zh) * 2023-08-25 2023-10-13 遵义医科大学珠海校区 一种抗炎镇痛中药组合物及其制备方法与应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103520335B (zh) * 2013-10-22 2014-12-10 青岛市市立医院 一种治疗牙龈肿痛的中药组合物
CN104435232B (zh) * 2014-11-12 2016-12-07 安徽智博新材料科技有限公司 一种用于治疗牙痛的中药组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1243745A (zh) * 1999-07-22 2000-02-09 蒋勤 一种治疗头痛症的芎芷液中成药

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1569048A (zh) * 2003-07-13 2005-01-26 毛友昌 清眩新的制备工艺及其制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1243745A (zh) * 1999-07-22 2000-02-09 蒋勤 一种治疗头痛症的芎芷液中成药

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
WANG,K. ET AL.: "Xiongzhi Shigao Yin for Headache on 50 Cases", SHANXI JOURNAL OF TRADITIONAL CHINESE MEDICINE, vol. 6, no. 10, 1985, pages 447 *
YANG, G.: "Yatong Pulvis for Wisdom Tooth Pericoronitis on 112 Cases", JOURNAL OF TRADITIONAL CHINESE MEDICINE, no. 12, 1992, pages 32 *
ZHANG, R. ET AL.: "Yatong Fang for Toothache", JOURNAL OF YUNNAN COLLEGE OF TRADITIONAL CHINESE, no. 3, 1991, pages 17 *
ZHOU, Y.: "Self-formulated navel Applied Chuan Baishi Pulvis for treatment of Migraine", ZHEJIANG JOURNAL OF TRADITIONAL CHINESE MEDICINE, vol. 25, no. 5, 1990, pages 198 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103585289A (zh) * 2012-08-15 2014-02-19 四川济生堂药业有限公司 一种预防或治疗肠易激综合症的药物组合物
CN112618648A (zh) * 2020-12-25 2021-04-09 李玲 一种快速退热的中药组合物及其制备方法
CN116870076A (zh) * 2023-08-25 2023-10-13 遵义医科大学珠海校区 一种抗炎镇痛中药组合物及其制备方法与应用
CN116870076B (zh) * 2023-08-25 2024-04-09 遵义医科大学珠海校区 一种抗炎镇痛中药组合物及其制备方法与应用

Also Published As

Publication number Publication date
CN101254227B (zh) 2013-08-07
CN101254227A (zh) 2008-09-03

Similar Documents

Publication Publication Date Title
TWI792162B (zh) 一種具有清肺排毒功能的中藥複方及其應用
CN101987123B (zh) 一种用于缓解颈肩、腰腿、关节、肌肉疼痛的药物及其制备方法
CN101380417B (zh) 快速治疗荨麻疹的制剂
CN100384467C (zh) 一种治疗肝炎和脂肪肝的中药组合物
WO2009117953A1 (fr) Composition pharmaceutique ayant un effet antidépresseur et anxiolytique
CN101940658B (zh) 一种治疗牙痛的中药组合物及其制备方法
CN101391058A (zh) 一种清热解毒制剂
CN111150792A (zh) 具有抗新型冠状病毒SARS-Cov-2作用的中药组合物及其制备方法与应用
CN105902906A (zh) 一种治疗风寒感冒咳嗽的中药组合物及其制备方法
CN103007012B (zh) 一种治疗牙疼的中药组合物及其制备方法
JP2004161732A (ja) Ｈｉｖ／エイズ患者の処置のための生薬医薬組成物
WO2009117952A1 (fr) Composition pharmaceutique anti-tussive, anti-asthme, agissant contre la gorge sèche, anti-mucosique, et son procédé de préparation
WO2009117936A1 (fr) Composition pharmaceutique à effets antipyrétiques, anti-inflammatoires et analgésiques et son procédé de préparation
WO2021208335A1 (fr) Composition de médecine traditionnelle chinoise capable d'éliminer les toxines, de supprimer la moiteur, et de décongestionner la gorge, et son application
CN1977959A (zh) 一种综合调理人体机能的中药复方制剂及其制备方法
Jiang et al. Post-infectious cough of different syndromes treated by traditional Chinese medicines: A review
CN101020027B (zh) 预防和治疗艾滋病的药物组合物及其制备方法和用途
CN103961614A (zh) 用于治疗呼吸系统疾病的中药组合物及其制备方法和用途
CN103656122A (zh) 治疗外感热病的中药及其制备方法
CN101085088A (zh) 治疗前列腺增生的中药方剂
CN100528212C (zh) 治疗复发性口腔溃疡的中药及其制备方法
CN106177542A (zh) 一种清暑解毒的中药组方及其制品
CN105343551A (zh) 一种治疗干燥综合征的药物组合物及其制备方法和应用
CN111265554A (zh) 抗病毒复方组合物在抗hiv病毒、sars病毒和白血病病毒中的应用
CN101991793A (zh) 治疗非特异性溃疡性结肠炎的药物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09723970

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09723970

Country of ref document: EP

Kind code of ref document: A1